Literature DB >> 32718500

Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease.

Zachary Winder1, Donna Wilcock1, Gregory A Jicha2.   

Abstract

This article focuses on current clinical laboratory testing to diagnose Alzheimer disease and monitor its progression throughout its disease course. Several clinically available tests focus on analysis of amyloid and tau levels in cerebrospinal fluid as well as autosomal dominant and risk factor genes. Although the current armament of clinical laboratory testing is limited by invasiveness of cerebrospinal fluid collection, rarity of autosomal dominant genetic mutations, and uncertainties of risk inherent in nonpenetrant genes, the field is poised to advance the clinical repertoire of laboratory diagnostic testing.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Cerebrospinal fluid (CSF); Mild cognitive impairment (MCI); Phospho-tau; Preclinical AD; Tau; β-amyloid (Aβ)

Mesh:

Substances:

Year:  2020        PMID: 32718500     DOI: 10.1016/j.cll.2020.05.003

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  1 in total

1.  Examining the association between blood-based biomarkers and human post mortem neuropathology in the University of Kentucky Alzheimer's Disease Research Center autopsy cohort.

Authors:  Zachary Winder; Tiffany L Sudduth; Sonya Anderson; Ela Patel; Janna Neltner; Barbara J Martin; Katherine E Snyder; Erin L Abner; Gregory A Jicha; Peter T Nelson; Donna M Wilcock
Journal:  Alzheimers Dement       Date:  2022-03-10       Impact factor: 16.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.